Drug Profile


Alternative Names: ALX-0081; ALX-0681; Anti-von Willebrand factor Nanobody - Ablynx; Anti-vWF inhibitor - Ablynx; Anti-vWF nanobody - Ablynx

Latest Information Update: 03 Oct 2016

Price : $50

At a glance

  • Originator Ablynx
  • Class Anticoagulants; Antithrombotics; Proteins
  • Mechanism of Action Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Thrombotic thrombocytopenic purpura
  • Discontinued Thrombosis

Most Recent Events

  • 29 Sep 2016 Adverse events data from a phase II TITAN trial in Thrombotic thrombocytopenic purpura released by Ablynx
  • 16 Aug 2016 Ablynx initiates enrolment in the (Post-HERCULES) trial for Thrombotic thrombocytopenic purpura in Austria, Hungary and Spain (EudraCT2016-001503-23)
  • 29 Oct 2015 Phase-III clinical trials in Thrombotic thrombocytopenic purpura (Adjunctive treatment) in Spain (IV) (EudraCT 2015-001098-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top